Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: How worried should we be?

Journal of Clinical Oncology

Volumn 28, Issue 21, 2010, Pages 3407-3410

  Morris, Patrick G ^a   Hudis, Clifford A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHROMOSOME 17; CONGESTIVE HEART FAILURE; DRUG SAFETY; EDITORIAL; FOLLOW UP; GENE EXPRESSION; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; GENETICS; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; NOTE;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HEART DISEASES; HEART FAILURE; HUMANS; RECEPTOR, ERBB-2; VENTRICULAR FUNCTION, LEFT;

EID: 77955296163     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.0125     Document Type: Editorial

References (33)

1. Dawood SS, Kristine B, Hortobagyi GN, et al: Prognosis of women with stage IV breast cancer by HER2 status and trastuzumab treatment: An institutional based review. J Clin Oncol 26:45S, 2008 (suppl; abstr 1018)
2. Hudis CA: Trastuzumab: Mechanism of action and use in clinical practice. N Engl J Med 357:39-51, 2007
3. Joensuu H, Bono P, Kataja V, et al: Fluorouacil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol 27:5685-5692, 2009
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
5. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
6. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu-positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium, 2009 (abstr 62)
7. Slamon D, Eiermann W, Robert N, et al: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium, 2006 (abstr 52)
8. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002 (Pubitemid 34177427)
9. Perez EA, Suman VJ, Davidson NE, et al: Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. J Clin Oncol 23:17S, 2005 (suppl; abstr 556)
10. Geyer C, Bryant J, Romond E, et al: Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC). San Antonio Breast Cancer Symposium, 2003 (abstr 23)
11. Russell S, Blackwell K, Lawrence J, et al: Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 28:3416-3421, 2010
12. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
13. Procter M, Suter T, de Azambuja E, et al: Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 28:3422-3428, 2010
14. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007 (Pubitemid 46039831)
15. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859-3865, 2007
16. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005 (Pubitemid 46657378)
17. Rastogi P, Jeong J, Geyer CE, et al: Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab(H). J Clin Oncol 25:964S, 2007 (suppl; abstr LBA513)
18. Dang C, Fornier M, Sugarman S, et al: The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol 26:1216-1222, 2008
19. Morris P, Dickler M, McArthur H, et al: Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol 27:6117-6123, 2009
20. Dawood S, Gonzalez-Angulo AM, Peintinger F, et al: Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: A retrospective review of the M. D. Anderson experience. Cancer 110:1195-1200, 2007
21. Buzdar AU, Valero V, Ibrahim NK, et al: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-233, 2007 (Pubitemid 46121873)
22. Gianni L, Eiermann W, Semiglazov V, et al: Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: Primary efficacy analysis of the NOAH trial. San Antonio Breast Cancer Symposium, 2008 (abstr 31)
23. Morris P, Chen C, Lin N, et al: Troponin I and C-reactive protein as biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib. Eur J Cancer Supplements 2:271, 2009 (suppl 7; abstr 5034)
24. Gennari A, Sormani MP, Pronzato P, et al: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 100:14-20, 2008 (Pubitemid 351767337)
25. Pritchard KI, Shepherd LE, O'Malley FP, et al: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111, 2006 (Pubitemid 43736610)
26. Bartlett JM, Munro A, Cameron DA, et al: Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 26:5027-5035, 2008
27. Burden DA, Osheroff N: Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1400:139-154, 1998 (Pubitemid 28475100)
28. O'Malley FP, Chia S, Tu D, et al: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101:644-650, 2009
29. McArthur H, Tan L, Patil S, et al: High resolution representational oligonucleotide microarray analysis (ROMA) suggests that TOPO2 and HER2 coamplification is uncommon in human breast cancer. San Antonio Breast Cancer Symposium, 2008 (abstr 2023)
30. Desmedt C, Azambuja E, Larsimont D, et al: Predicting the efficacy of anthracyclines in breast cancer (BC) patients: Results of the neoadjuvant TOP trial. J Clin Oncol 27:12S, 2009 (suppl; abstr 523)
31. Gianni L, Norton L, Wolmark N, et al: Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 27:4798-4808, 2009
32. U.S. National Institutes of Health: Trastuzumab for 6 months or 1 year in treating women with nonmetastatic breast cancer that can be removed by surgery. http://clinicaltrials.gov/show/NCT00381901
33. U.S. National Institutes of Health: The Synergism or Long Duration (SOLD) Study. http://clinicaltrials.gov/show/NCT00593697